Format

Send to

Choose Destination
Bull Cancer. 2015 Mar;102(3):245-55. doi: 10.1016/j.bulcan.2015.01.010. Epub 2015 Mar 7.

[Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review].

[Article in French]

Author information

1
Institut Bergonié, département d'oncologie médicale, 33076 Bordeaux cedex, France; Institut Bergonié, département de bio-pathologie, laboratoire de génétique moléculaire, unité d'oncogénétique, 33076 Bordeaux cedex, France.
2
Institut Bergonié, département de bio-pathologie, laboratoire de génétique moléculaire, unité d'oncogénétique, 33076 Bordeaux cedex, France.
3
Institut Bergonié, département d'oncologie médicale, 33076 Bordeaux cedex, France.
4
Institut Bergonié, département d'oncologie médicale, 33076 Bordeaux cedex, France. Electronic address: M.Debled@bordeaux.unicancer.fr.

Abstract

BRCA1 and BRCA2 mutations account for 40% of cancer predisposition gene mutations identified in the current French diagnostic setting. The proteins encoded by these genes are implicated in DNA repair pathways. As a result, loss of BRCA1 or BRCA2 function may modify chemo-sensitivity. This literature review aims to determine whether BRCA1 mutation status should influence the choice of systemic treatment in breast cancer. Fourteen articles and four abstracts from 12 retrospective analyses and 6 prospective studies were identified in the literature review. CMF-type and taxane-based protocols appear to be insufficiently effective, while anthracycline activity does not seem to be affected by BRCA1 status. BRCA1-mutated tumours appear to be highly sensitive to platinum, in both the neoadjuvant and metastatic setting. Olaparib, a PARP inhibitor, has only been evaluated in one study in metastatic patients, with promising results. The presence of a BRCA1 mutation can lead to an adaptation of therapies in the metastatic stages in breast cancer. The rapid identification of BRCA1 mutations and the adaptation of treatment according to this status in the (neo)adjuvant setting is likely to become a reality in the coming years.

KEYWORDS:

BRCA1; Breast cancer; Cancer du sein; Chemotherapy; Chimiothérapie; Literature review; Metastatic; Métastatique; Neoadjuvant; Néoadjuvant; Revue de la littérature

PMID:
25758301
DOI:
10.1016/j.bulcan.2015.01.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center